Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

At Least 1 Year on Bisphosphonates Needed for Fracture Prevention

Lisa Rapaport  |  

“While our results suggest that bisphosphonate therapy is likely to be beneficial for most older postmenopausal women with osteoporosis, it is important to consider individual values and preferences,” Dr. Deardorff says.

Reference

  1. Deardorff WJ, Cenzer I, Nguyen B, et al. Time to benefit of bisphosphonate therapy for the prevention of fractures among postmenopausal women with osteoporosis: A meta-analysis of randomized clinical trials. JAMA Intern Med. 2021 Nov 22;e216745. Online ahead of print.

Related Articles

    Osteoporosis Experts Discuss Bisphosphonate Holidays

    ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday?…

    Do Bisphosphonates Reduce Cardiovascular-Related Mortality?

    It is well known that hip fractures are associated with significant morbidity and mortality: Mortality increases 15–25% in the year following a hip fracture.1–5 We know that treating osteo­porosis prevents fractures and improves patient survival. But is there a relationship beyond this? Several studies have found that bisphosphonate therapy is associated with a reduction in…